Tau 聚集体代表阿尔茨海默病 (AD) 和其他形式的痴呆症的关键病理学。跨定义大脑区域的 Tau 神经原纤维缠结的程度很好地对应于观察到的 AD 认知下降水平。化合物1 ( PI-2620 ) 最近被确定为用于 AD 和非 AD tau 病变的有前途的 Tau 正电子发射断层扫描示踪剂。为了评估N原子位置对 Tau 和脱靶结合的影响,PI-2620的三环核心类似物制备了不同位置的氮原子。使用人 AD 脑匀浆评估对聚集 Tau 的亲和力,并在单胺氧化酶 A (MAO-A) 竞争测定中评估它们的脱靶结合。新型三环核心衍生物均显示出较差的 Tau 结合或 MAO-A 脱靶选择性,表明PI-2620是与 Tau 高亲和力结合和高 MAO-A 选择性的最佳设计。
[EN] NOVEL METHOD OF PREPARING AN IMAGING COMPOUND<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ D'IMAGERIE
申请人:AC IMMUNE SA
公开号:WO2019145294A1
公开(公告)日:2019-08-01
The present invention relates to a novel method of preparing a compound of the formula I. Diagnostic compositions and their use in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET) imaging are also disclosed.
[EN] DIAGNOSTIC COMPOSITIONS FOR PET IMAGING, A METHOD FOR MANUFACTURING THE DIAGNOSTIC COMPOSITION AND ITS USE IN DIAGNOSTICS<br/>[FR] COMPOSITIONS DIAGNOSTIQUES POUR L'IMAGERIE TEP, PROCÉDÉ DE FABRICATION DE LA COMPOSITION DIAGNOSTIQUE, ET UTILISATION DE CELLE-CI DANS DES DIAGNOSTICS
申请人:AC IMMUNE SA
公开号:WO2019145293A1
公开(公告)日:2019-08-01
The present application relates to a diagnostic composition comprising: a. a compound of Formula I, b. ethanol, c. water, and d. a hydroxycarboxylic acid, a salt of a hydroxycarboxylic acid or a mixture thereof. The diagnostic composition can be used in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET). The present invention also relates to a method of preparing the claimed diagnostic composition.
[EN] 9H-PYRROLO-DIPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 9H-PYRROLO-DIPYRIDINE
申请人:UCB BIOPHARMA SPRL
公开号:WO2018024642A1
公开(公告)日:2018-02-08
The invention relates to 9H-pyrrolo-dipyridine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of Tau aggregates.
The present invention relates to novel compounds of the formula (II)
that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
The present invention relates to novel compounds of the formula (II)
that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
本发明涉及式 (II) 的新型化合物
本发明涉及一种新型的式 (II) 化合物,该化合物可利用正电子发射断层扫描 (PET) 成像技术选择性地检测与 Tau 聚集有关的疾病和异常,如阿尔茨海默病和其他 Tau 病。